{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:44Z","timestamp":1787027804726,"version":"build-2736575974"},"reference-count":59,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ferring Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Bladder cancer is the ninth most prevalent cancer globally. Most cases are urothelial carcinoma, classified as non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancer (MIBC); approximately 70% are diagnosed as NMIBC. Current standard of care for high-risk NMIBC includes transurethral tumour resection, followed by intravesical therapy with Bacillus Calmette-Gu\u00e9rin (BCG). However, significant unmet needs persist due to disease recurrence, BCG unresponsiveness, or progression to MIBC. Radical cystectomy is recommended after BCG unresponsiveness but may not be viable due to its invasiveness and morbidity. The paucity of treatment options for BCG-unresponsive NMIBC has driven research into alternatives such as gene therapy. The bladder\u2019s anatomy allows direct vector\u2013tumour contact, while urine and tissue samples allow for easy monitoring of therapeutic effects. Methods: This narrative review integrates findings from recent clinical and preclinical studies identified through comprehensive searches of peer-reviewed literature to provide an overview of the current landscape of gene therapy for BCG-unresponsive NMIBC. Results: Nadofaragene firadenovec, a recombinant adenovirus delivering interferon alpha-2b (IFN\u03b12b), is the first FDA-approved gene therapy for BCG-unresponsive NMIBC with carcinoma in situ (CIS). A phase III nadofaragene firadenovec study (NCT02773849) demonstrated a 53% complete response (CR) rate at 3 months; and 43% of patients with CIS had bladder preservation at 60 months. Cretostimogene grenadenorepvec (CG0070), an oncolytic vector, demonstrated a 47% 6-month CR rate in a phase II study (NCT02365818). Detalimogene voraplasmid (EG-70), a nonviral gene therapy, demonstrated a 47% 6-month CR in a phase I\/II study (NCT04752722). Future advances are likely to focus on patient selection, novel vectors, and combination strategies to improve treatment outcomes. Conclusions: Gene therapy represents a significant addition to the bladder cancer treatment landscape by offering bladder-sparing alternatives where conventional therapies are limited.<\/jats:p>","DOI":"10.3390\/cancers17223631","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T10:56:47Z","timestamp":1762945007000},"page":"3631","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Gene Therapy for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: Current Evidence and Future Directions"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4227-7687","authenticated-orcid":false,"given":"Philippe","family":"Pinton","sequence":"first","affiliation":[{"name":"Ferring Pharmaceuticals, Ferring International PharmaScience Centre, Amager Strandvej, 2770 Kastrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, nccn clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Deininger, S., Torzsok, P., Mitterberger, M., Pallauf, M., Oswald, D., Deininger, C., and Lusuardi, L. (2022). From interferon to checkpoint inhibition therapy-a systematic review of new immune-modulating agents in bacillus calmette-guerin (bcg) refractory non-muscle-invasive bladder cancer (nmibc). Cancers, 14.","DOI":"10.3390\/cancers14030694"},{"key":"ref_4","unstructured":"Leslie, S.W., Soon-Sutton, T.L., and Aeddula, N.R. (2025). Bladder cancer. StatPearls, StatPearls Publishing."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Martini, A., Tholomier, C., Mokkapati, S., and Dinney, C.P.N. (2023). Interferon gene therapy with nadofaragene firadenovec for bladder cancer: From bench to approval. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1260498"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00345-018-2553-7","article-title":"The development of interferon-based gene therapy for bcg unresponsive bladder cancer: From bench to bedside","volume":"37","author":"Duplisea","year":"2019","journal-title":"World J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bjurlin, M.A., and Matulewicz, R.S. (2021). Comprehensive Diagnostic Approach to Bladder Cancer, Springer.","DOI":"10.1007\/978-3-030-82048-0"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Herranz, R., Oto, J., Plana, E., Fernandez-Pardo, A., Cana, F., Martinez-Sarmiento, M., Vera-Donoso, C.D., Espana, F., and Medina, P. (2021). Circulating cell-free DNA in liquid biopsies as potential biomarker for bladder cancer: A systematic review. Cancers, 13.","DOI":"10.3390\/cancers13061448"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13193-018-0728-8","article-title":"Low-grade, multiple, ta non-muscle-invasive bladder tumors: Tumor recurrence and worsening progression","volume":"9","author":"Nerli","year":"2018","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"TPS4626","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4626","article-title":"A phase 1\/2 study of eg-70 (detalimogene voraplasmid) intravesical monotherapy for patients with bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ","volume":"42","author":"Bryce","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Narayan, V.M., Meeks, J.J., Jakobsen, J.S., Shore, N.D., Sant, G.R., and Konety, B.R. (2024). Mechanism of action of nadofaragene firadenovec-vncg. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1359725"},{"key":"ref_12","unstructured":"Food and Drug Administration (2024, September 07). Bcg-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drug and Biological Products for Treatment, Available online: https:\/\/www.fda.gov\/media\/101468\/download."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rad-ifnalpha\/syn3 for patients with high-grade, bacillus calmette-guerin-refractory or relapsed non-muscle-invasive bladder cancer: A phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","unstructured":"Babjuk, M., Bohle, A., Burger, M., Comperat, E., Kaasinen, E., Palou Redorta, J., van Rhijn, B., Roupret, M., Shariat, S., and Sylvester, R. (2024, August 07). Statement Concerning the Shortage of BCG Vaccine from the EAU Guidelines Panel on Non-Muscle Invasive Bladder Cancer. Available online: https:\/\/d56bochluxqnz.cloudfront.net\/documents\/guideline-publications\/non-muscle-invasive-bladder-cancer\/NMIBC-Guidelines-Panel-Statement-Concerning-Shortage-of-BCG-Vaccine.pdf."},{"key":"ref_15","unstructured":"American Urological Association (2025, November 08). Important Message About the BCG Shortage. Available online: https:\/\/www.auanet.org\/about-us\/bcg-shortage-info."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/SPC.0000000000000587","article-title":"Emerging treatment options for bacillus calmette-guerin-unresponsive non-muscle invasive bladder cancer","volume":"16","author":"Kokorovic","year":"2022","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus calmette-gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/iju.14281","article-title":"Clinical practice guidelines for bladder cancer 2019 update by the Japanese urological association: Summary of the revision","volume":"27","author":"Matsumoto","year":"2020","journal-title":"Int. J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Miyake, M., Iida, K., Nishimura, N., Miyamoto, T., Fujimoto, K., Tomida, R., Matsumoto, K., Numakura, K., Inokuchi, J., and Morizane, S. (2021). Non-maintenance intravesical bacillus calmette\u2013gu\u00e9rin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: A retrospective non-randomized comparative study. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-07966-7"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1007\/s10147-021-01988-8","article-title":"Bacillus calmette-gu\u00e9rin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy","volume":"26","author":"Iida","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_21","unstructured":"U.S. Food and Drug Administration (2024, August 07). Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-first-adenoviral-vector-based-gene-therapy-high-risk-bacillus-calmette-Guerin."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/JU.0000000000004020","article-title":"Efficacy of intravesical nadofaragene firadenovec for patients with bacillus calmette-gu\u00e9rin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial","volume":"212","author":"Narayan","year":"2024","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1200\/JCO.2024.42.16_suppl.4601","article-title":"Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/01.JU.0001015816.87470.c9.02","article-title":"Pivotal results from BOND-003: A phase 3, single-arm study of intravesical crestotimogene grenadenorepvec for the treatment of high risk, BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ","volume":"211","author":"Tyson","year":"2024","journal-title":"J. Urol."},{"key":"ref_26","first-page":"S48","article-title":"Legend, a phase 1\/2 study of detalimogene voraplasmid (EG-70) intravesical monotherapy demonstrated clinical responses in BCG-unresponsive NMIBC patients with CIS","volume":"42","author":"Steinberg","year":"2024","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/01.JU.0001015816.87470.c9.08","article-title":"Legend: A phase 1\/2 study of EG-70 (detalimogene voraplasmid), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS)","volume":"211","author":"Kalota","year":"2024","journal-title":"J. Urol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1590\/s1679-45082017rb4024","article-title":"Gene therapy: Advances, challenges and perspectives","volume":"15","author":"Goncalves","year":"2017","journal-title":"Einstein"},{"key":"ref_29","unstructured":"(2025, November 08). Highlights of Prescribing Information: Adstiladrin (Nadofaragene Firadenovec-Vncg), Available online: https:\/\/www.fda.gov\/media\/164029\/download?attachment."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ymthe.2004.05.027","article-title":"Intravesical Ad-IFN\u03b1 causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-\u03b1 protein","volume":"10","author":"Benedict","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/sj.cgt.7700865","article-title":"Efficacy of a single intravesical treatment with Ad-IFN\/Syn 3 is dependent on dose and urine IFN concentration obtained: Implications for clinical investigation","volume":"13","author":"Tao","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/sj.cgt.7700364","article-title":"Interferon \u03b12b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers","volume":"8","author":"Johnson","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Guerin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1245\/s10434-016-5300-6","article-title":"Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon \u03b12b formulated in Syn3 for failures of bacillus calmette-guerin (BCG) therapy in nonmuscle invasive bladder cancer","volume":"23","author":"Navai","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S1492","DOI":"10.1016\/S0302-2838(24)01158-8","article-title":"A0583\u2014Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial","volume":"85","author":"Boorjian","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/01.JU.0001111604.90306.91.02","article-title":"Final results: Bond-003 cohort c- phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk bcg-unresponsive non-muscle invasive bladder cancer with carcinoma in situ","volume":"213","author":"Tyson","year":"2025","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1200\/JCO.2025.43.5_suppl.802","article-title":"Preliminary results from LEGEND: A phase 2 study of detalimogene voraplasmid (EG-70), a novel, non-viral intravesical gene therapy for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)","volume":"43","author":"Taylor","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.2025.43.5_suppl.716","article-title":"Real-world outcomes of nadofaragene firadenovec in BCG-unresponsive non-muscle invasive bladder cancer","volume":"43","author":"Moyer","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e16608","DOI":"10.1200\/JCO.2025.43.16_suppl.e16608","article-title":"ABLE-41, a real-world evidence study for bladder cancer patients treated with nadofaragene firadenovec: Baseline patient characteristics and demographics","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_41","unstructured":"Inoue, K., Kikuchi, E., Nishiyama, H., and Nasu, Y. (2025, January 19). Efficacy and safety of nadofaragene firadenovec for BCG-Unresponsive non\u2013muscle-invasive bladder cancer: Initial results From an ongoing Japanese phase 3 trial. Proceedings of the 112th Annual Meeting of the Japanese Urological Association, Fukuoka, Japan."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"TPS891","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4630","article-title":"ABLE-22: Safety and efficacy evaluation of nadofaragene firadenovec alone or in combination with chemotherapy or immunotherapy\u2014A randomized, open-label, phase 2 study","volume":"43","author":"Daneshmand","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"TPS888","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4632","article-title":"ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non\u2013muscle-invasive bladder cancer","volume":"43","author":"Shore","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_44","unstructured":"ClinicalTrials.gov (2025, July 04). Low-Grade UTUC Treated with Nadofaragene Firadenovec Administered to Renal Pelvis (LUNAR), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06668493?term=AREA%5BBasicSearch%5D(AREA%5BLeadSponsorName%5D(ferring))&rank=2."},{"key":"ref_45","unstructured":"CG Oncology (2024, September 02). CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. Available online: https:\/\/cgoncology.com\/cg-oncology-receives-both-fda-fast-track-and-breakthrough-therapy-designation-for-cretostimogene-grenadenorepvec-in-high-risk-bcg-unresponsive-non-muscle-invasive-bladder-cancer\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"TPS715","DOI":"10.1200\/JCO.2024.42.4_suppl.TPS715","article-title":"PIVOT-006: A phase 3, randomized study of cretostimogene grenadenorepvec versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer (IR-NMIBC) following transurethral resection of bladder tumor (TURBT)","volume":"42","author":"Svatek","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_48","first-page":"51","article-title":"PIVOT-006: A phase 3, randomized study of adjuvant intravesical cretostimogene grenadenorepvec versus surveillance for the treatment of intermediate-risk non-muscle invasive bladder cancer","volume":"43","author":"Svatek","year":"2025","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"TPS901","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS901","article-title":"CORE-008: A phase 2, multi-arm, multi-cohort, open-label study to evaluate intravesical cretostimogene grenadenorepvec in participants with high-risk non-muscle invasive bladder cancer","volume":"43","author":"Bivalacqua","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"TPS902","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS902","article-title":"Expanded access program of cretostimogene grenadenorepvec in patients with non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin","volume":"43","author":"Psutka","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2021.12.009","article-title":"Antiadenovirus antibodies predict response durability to nadofaragene firadenovec therapy in BCG-unresponsive non-muscle-invasive bladder cancer: Secondary analysis of a Phase 3 clinical trial","volume":"81","author":"Mitra","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/MS9.0000000000001488","article-title":"Nadofaragene: A new era of precision medicine for bladder cancer","volume":"86","author":"Zehra","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bju.16332","article-title":"Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC","volume":"134","author":"Rieger","year":"2024","journal-title":"BJU Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials\u2014A primer for researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin. Epidemiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"100403","DOI":"10.1016\/j.jcpo.2023.100403","article-title":"Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016-2021","volume":"35","author":"Wang","year":"2023","journal-title":"J. Cancer Policy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ucl.2019.09.011","article-title":"Intravesical gene therapy","volume":"47","author":"Narayan","year":"2020","journal-title":"Urol. Clin. N. Am."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1097\/NCC.0000000000000606","article-title":"Quality of life in non-muscle-invasive bladder cancer survivors: A systematic review","volume":"42","author":"Jung","year":"2019","journal-title":"Cancer Nurs."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: Costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur. Urol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3631\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:23:19Z","timestamp":1763097799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":59,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17223631"],"URL":"https:\/\/doi.org\/10.3390\/cancers17223631","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}